As reported in Table 1, the three different groups, Aβ+Tau, Aβ-Tau, and non-AD (four patients per group), were selected to have a very low variability compared to the average value of the different markers used for their characterization biochemistry of being AD or non-AD subjects. The gene discussed is MAPT; the disease is Alzheimer disease.